Clinical Trials Browser

Phase 2 × Nelfinavir × Plasma cell × Clear all

NCT02188537 2019-06-26

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Phase 2 Completed

Neoplasms, Plasma Cell